. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: Lancet Child Adolesc Health. 2017 Nov 3;2(1):25–34. doi: 10.1016/S2352-4642(17)30130-X

Table 3.

Overall OMA response rate, by randomized treatment arm

	Randomized to IVIG+ (n=26)	Randomized to NO-IVIG (n=27)	Total (n=53)	P value
OMA Responders	21 (81%)	11 (41%)	32 (60%)	0.0029^*
OMA Non-responders	5 (19%)	16 (59%)	21 (40%)
Reasons for OMA non- response:
Crossed over from NO- IVIG to IVIG+ only	N/A	9 (33%)	9 (17%)
Crossed over from NO- IVIG to IVIG+ then switched to ACTH	N/A	3 (11%)	3 (6%)
Switched to ACTH only	3 (12%)	0 (0%)	3 (6%)
Stable disease	2 (8%)	4 (15%)	6 (11%)
OMA Events	12 (46%)	19 (70%)	31 (58%)

In a secondary analysis of 52 patients who received therapy and completed at least one follow-up assessment of OMA response, p=0.0044.

N/A-not applicable